Investor relations

2022 Highlights

Introduction and background

The Annual Report and Accounts have been delayed following the discovery of the events outlined in the RNS announcements summarised below, which set out the background that is relevant for shareholders to review since the end of FY22.

On 9 March 2023, the Company released two RNS announcements collectively stating that:

The Board had become aware of significant, sophisticated and potentially fraudulent irregularities which related to received purchase orders and related revenue and bookings, as represented by one senior sales employee (the “Irregularities”).
As a result of the identification of the Irregularities, the Company had no confidence in its announced FY22 bookings expectations.
The Company would conduct an investigation with external legal and professional advisers into the Irregularities and its true financial position.
Following a request from the Company, AIM had suspended trading in the Company’s shares.

On 10 March 2023, the Company released an RNS announcement stating that:

It had appointed FRP Advisory to lead an independent investigation into the Irregularities (the “Independent Investigation”).
The Company had formed an investigation committee comprising independent non-executive directors to support and facilitate the investigation process.

On 3 April 2023 and 28 April 2023, the Company released RNS announcements collectively stating that the conclusions of the Independent Investigation concluded that:

All of the purchase orders associated with one senior sales employee were illegitimate.
All other purchase orders (i.e. those not associated with or secured by the senior sales employee in question) were legitimate.
Accordingly, estimated revenue for FY22 referenced in the Trading Update dated 11 January 2023 should have been $9.7 million (unaudited) as compared with not less than $24m (unaudited) and estimated bookings should have been $11.4m (unaudited) compared with $127m (unaudited).
An update on key initiatives following FRP Advisory’s continuing work to examine relevant processes and controls and other steps being taken to improve the Company’s internal processes would be provided in the Annual Report and Accounts for FY22.

On 20 April 2023, the Company released an RNS announcement stating that it had been notified by the Financial Conduct Authority (the “FCA”) of its commencement of an investigation into the Company (the “FCA Investigation”). The FCA Investigation relates to certain regulatory announcements released by the Company during the period 1 May 2021 to 9 March 2023, which may have materially mis-stated the Company’s financial position.

On 15 May 2023, the Company released an RNS announcement stating that:

Having reviewed various options, the Board believed that the most appropriate strategy was to launch an equity fundraise towards the end of June 2023 of $30 million (the “Fundraising”).
The Company had commenced a deep transformation recovery program.

On 6 June 2023, the Company released an RNS announcement stating that earlier that day at a general meeting of the Company, shareholders had authorised the Company to allot new ordinary shares in order to support the Fundraising with 97.8% of votes cast in favour of both resolutions.

On 3 July 2023, the Company launched the Fundraising to raise gross proceeds of $30 million at a price of 50 pence per share and, on 4 July the Company released an RNS announcement stating that it had successfully completed the Fundraising.

On 5 July 2023, the Company issued an RNS to update shareholders on the timetable associated with the Fundraising stating that “In working to complete the fundraise process, the Company has encountered the requirement under Jersey law to seek further shareholder approval to increase its authorised share capital in order to issue the Offer Shares pursuant to the Fundraise.” Completion of this step means settlement of the Fundraise and Admission are now expected to take place on 25 July 2023, subject to the passing of the necessary resolution by shareholders.

Financial highlights

Cirata is a data activation platform for achieving data transfer at scale.

Cirata makes petabyte and exabyte-scale data trapped in on-premises data lakes and IoT/edge/file systems actionable by delivering continuous cloud data migrations in real time with no business disruption or data loss. Cirata activates data to power artificial intelligence (“AI”) and machine learning, create new services, and transform businesses.

DISCLAIMER – IMPORTANT

ELECTRONIC VERSIONS OF THE INFORMATION AND MATERIALS YOU ARE SEEKING TO ACCESS, TO WHICH THIS GATEPOST GIVES ACCESS, ARE BEING MADE AVAILABLE ON THIS WEBSITE BY CIRATA PLC (THE “COMPANY”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.

THESE MATERIALS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN OR RESIDENT IN (OR ORGANISED OR INCORPORATED UNDER THE LAWS OF) THE UNITED STATES, THE COMMONWEALTH OF AUSTRALIA, ITS TERRITORIES AND POSSESSIONS, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR SWITZERLAND, OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.

The information and materials you are seeking to access do not constitute or form a part of any offer to sell, or a solicitation of an offer to purchase or subscribe for, any securities of the Company in the United States (including any state, possession or territory) or any other jurisdiction where it is unlawful to do so. Any securities issued in connection with an offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “US Securities Act”), or under any applicable securities laws of any state, province, possession, territory, county or jurisdiction of the United States, Australia, Canada or Japan. Such securities may not be offered or sold in the United States or to, or for the account or benefit of, US persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration. Further, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities of the Company in the United States.

The information and materials you are seeking access to are only addressed to and directed at persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(E) of the prospectus regulation 2017/1129 ("Prospectus Regulation") (and any amendments thereto) (“Qualified Investors”). In addition, in the United Kingdom, the materials are being distributed only to, and are directed at Qualified Investors who (a) fall within the definition of "investment professionals" within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (b) are high net worth entities, and other persons as described in Article 49(2)(a) to (d) of the Order or, otherwise to persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which these materials relates are available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA other than the United Kingdom, and will be engaged in only with such persons.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be, released or otherwise forwarded, distributed or sent to any US persons or in or into the United States, Australia, Canada, Japan, or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them to any US persons or in, or into the United States, Australia, Canada, Japan, or any other jurisdiction in which such offers or sales are unlawful.

Confirmation of understanding and acceptance of disclaimer

By clicking “I CONFIRM” below, you:

(i) confirm that you have read and understood the disclaimer set out above, that you understand that it may affect your rights, that you agree to be bound by its terms and that you confirm that you are permitted to proceed to this part of the website;

(ii) certify that you are not a US person (as defined in Regulation S of the US Securities Act) or a resident of or located in the United States or a person acting on behalf of the foregoing and agree that you will not retransmit, send or otherwise transfer any of the information contained on this website to any US person or person in or resident in the United States; and

(iii) warrant that you are not a resident of or located in Australia, Canada or Japan or any other jurisdiction where accessing these materials is unlawful, and you agree that you will not retransmit, send or otherwise transfer any of the information contained on this website to any person in Australia, Canada, Japan or any other jurisdiction where to do so would breach applicable local law or regulation.

PLEASE NOTE that it is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should not continue to seek access to this area of the website.

Cirata Plc does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.

3497099 v2

I Disagree I CONFIRM